Displaying drugs 7726 - 7750 of 8030 in total
Coronavirus-Like Particle COVID-19 Vaccine
The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the...
Investigational
Matched Description: … vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of ... 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of …
D-Glutamine
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
Experimental
Matched Description: … It is the principal carrier of nitrogen in the body and is an important energy source for many cells. …
Zebularine
A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.
Experimental
Matched Description: … It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as …
IR208
IR208 is a synthetic T-Cell receptor peptide
vaccine developed by Immune Response Corporation.
It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients. IR208 is currently undergoing Phase II
studies in a 200-patient trial.
Investigational
Matched Description: … It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients …
Pimagedine
Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.
Investigational
Matched Description: … Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease …
IMC-1C11
IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
Investigational
Matched Description: … IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma. …
Selisistat
Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.
Experimental
Matched Description: … Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase …
AdimrSC-2f
The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia . A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548].
Investigational
Matched Description: … A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548 …
CYC116
CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers.
Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which...
Investigational
Matched Description: … enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition of …
OPC-28326
At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, and mesenteric blood flows. It is the only clinical compound with this profile. It is currently being...
Investigational
Matched Description: … It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome …
NOX-100
NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple...
Investigational
Matched Description: … NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind …
Deanol
Deanol is commonly referred to as 2-(dimethylamino)ethanol, dimethylaminoethanol (DMAE) or dimethylethanolamine (DMEA). It holds tertiary amine and primary alcohol groups as functional groups. Deanol has been used in the treatment of attention deficit-hyperactivity disorder (ADHD), Alzheimer's disease, autism, and tardive dyskinesia. It has been also used as an ingredient in...
Experimental
Matched Description: … Deanol has been used in the treatment of attention deficit-hyperactivity disorder (ADHD), Alzheimer's …
Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
Umbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties. In comparison to bone-marrow derived MSCs, these cells are more resilient, easier to extract, and generally regarded as less immunogenic. The condition medium (CM) derived from these MSCs has also been implicated...
Investigational
Matched Description: … Many companies are creating their own version of this medium. ... One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product …
MultiStem
MultiStem is an intravenously-administered, off-the-shelf proprietary product developed which comprises Multipotent Adult Progenitor Cells (MAPCs). Like mesenchymal stem cells, MAPCs are derived from bone-marrow stroma and are non-hematopoietically adherent. They have immunomodulatory and pro-angiogenic properties while also being mostly non-immunogenic. Additional benefits of MultiStem include their low immunogenicity, meaning they...
Investigational
Matched Description: … The cells for creation of the product are isolated from a qualified donor and expanded on a large scale ... Additional benefits of MultiStem include their low immunogenicity, meaning they can be administered without …
Satraplatin
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
Investigational
Matched Description: … Satraplatin is a platinum compound that is currently under investigation as one treatment of patients …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune …
AdPEDF
AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors.
Investigational
Matched Description: … AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). …
Olesoxime
Olesoxime is a cholesterol-like small molecule that has demonstrated a remarkable neuroprotective profile in a battery of both in vitro and in vivo preclinical models. For example, it has demonstrated the ability to prevent neurodegeneration, enhance nerve function and accelerate neuroregeneration following nerve trauma.[A3282,A253233]
Investigational
Matched Description: … cholesterol-like small molecule that has demonstrated a remarkable neuroprotective profile in a battery of …
Epitestosterone
Epitestosterone is the 17-alpha isomer of testosterone, derived from pregnenolone via the delta5-steroid pathway, and via 5-androstene-3-beta,17-alpha-diol. Epitestosterone acts as an antiandrogen in various target tissues. The ratio between testosterone/epitestosterone is used to monitor anabolic drug abuse.
Experimental
Matched Description: … Epitestosterone is the 17-alpha isomer of testosterone, derived from pregnenolone via the delta5-steroid …
Masitinib
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
Investigational
Vet approved
Matched Description: … Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. …
Nadide
A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
Experimental
Matched Description: … A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate …
Afimetoran
Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8.[L32018, L32023] It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants).
Investigational
Matched Description: … Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8. …
ABX1100
ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle. It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.
Investigational
Matched Description: … It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease …
BNT162b3
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … deemed this compound as promising in preclinical trials and have decided to initiate further testing of …
Picrotoxin
A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the gamma-aminobutyric acid-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]
Experimental
Displaying drugs 7726 - 7750 of 8030 in total